Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rifamycin SV MMX for Traveler's Diarrhea in Children (12-17 Years)
NCT04027894Phase 2Not yet recruiting
- Sponsor
- RedHill Biopharma
- Start
- Jan 2024
- Primary completion
- Jan 2025
- Modality
- Small Molecules
01
Overview
A Phase 2 trial of rifamycin SV-MMX in traveler's diarrhea (TD), sponsored by RedHill Biopharma. Planned start Jan 2024; status: not yet recruiting.
02
Drugs
rifamycin SV-MMX
03
Conditions
traveler's diarrhea (TD)
Beyond the preview
Go deeper on NCT04027894.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04027894.